RhD immunoglobulin is used to prevent RhD alloimmunisation and subsequent haemolytic disease of the newborn in RhD negative women. It has been available in Australia since 1967.
The Blood Matters serious transfusion incident reporting (STIR) system has collected information on incidents, reactions and near misses relating to transfusion since 2007. Since reporting commenced, some common error themes emerged.
To understand current practice, Blood Matters conducted an audit to assess compliance with the current Australian guidelines.
- Research and reports
- Date published
- 21 Aug 2019
- 33 pages
Reviewed 22 August 2019